BioAdaptives, Inc. is an R&D-focused nutraceutical and medical device company developing natural, regenerative health products with minimal current revenue and a heavy reliance on external financing.

# Company Summary: BioAdaptives, Inc.

## Business Overview
- **Core Business**: Investigation, marketing, and distribution of natural plant, fungi, and algal-based products and medical devices aimed at improving health and wellness for humans and animals.
- **Focus Areas**:
  - Weight control
  - Antiviral functions
  - Anti-aging properties

## Product Development
- **Key Products in Development**:
  - **Zeranovia™**: Weight management supplement, currently in human clinical trials, expected to be commercially launched in Q2 2025. Made from natural ingredients, using proprietary methods to optimize nutrient availability, with demonstrated positive results in weight loss and muscle mass retention.
  - **Xcellara™**: Regenerative stem cell activator, in production, expected to sell commercially in April 2025.
  - **PawPa™ Regen**: Canine treat stem cell activator, supports anti-aging and wellness, expected to be delivered in April 2025 based on extensive trials involving humans, dogs, horses, hogs, and mice.
  - **MyndMed™**: Nootropic developed upon request of advisory board member, designed to improve memory, learning, mood, neuroprotection, and stress resilience through multiple pathways like acetylcholine, dopamine, GABA, antioxidants, and mitochondrial energy.

## Market & Marketing
- Uses a **Direct to Consumer (DTC)** digital marketing approach:
  - Social media, email, and website content
  - Targeted advertising and community-building around natural health solutions
- Strategic partnerships with telehealth platforms to promote and sell products
- Affiliate marketing with influencers and companies in the health/wellness space

## Manufacturing & Supplies
- Developed a product line utilizing algae and mushrooms starting in 2022.
- Outsources manufacturing, avoiding capital-intensive infrastructure.
- Purchased Lungflute™ medical device in April 2024, with no internal medical device manufacturing capabilities.

## Financial & Operational Data
- **Employees**: Currently, only one full-time executive employee (as of May 2024). The company relies on hourly labor and professional consultants as needed.
- **Customers**: No explicit number of customers provided; product sales are minimal.
- **Revenue**: For the years ending December 31, 2024, and 2023, revenue was approximately **$12,669** and **$28,565**, respectively.
- **Net Income/Loss**:
  - 2024: Loss of approximately **$899,161**
  - 2023: Loss of approximately **$712,466**
- **Market Capitalization**: The company's common stock is minimally traded and sporadically in the OTC Pink Sheets, with recent stock prices around $0.06 to $0.09 as of December 2024 and March 2025.

## Additional Details
- The company emphasizes research and development in all-natural supplement formulations, particularly those activating stem cells and their derivatives.
- It is not currently paying dividends; it issued a stock dividend in January 2025.
- The company relies heavily on external financing, including convertible debt, with no current cash flows to support operations independently.
- As of the latest filings, the company has a small but growing set of issued stock and preferred stock with enhanced voting rights. It has few full-time employees and depends on external consultants for operations.

**In summary**, BioAdaptives, Inc. is an R&D-focused nutraceutical and medical device company targeting wellness improvement through natural and regenerative products. Its operations remain limited, current revenues are minimal, and it is heavily reliant on external financing to support ongoing product development and commercialization efforts.

BioAdaptives, Inc. is a health and wellness company focused on developing and distributing natural plant, algal, and mushroom-based products for human and animal health.

# BioAdaptives, Inc. Overview

## Company Profile
- **Incorporation**: April 19, 2013, in Delaware.
- **Trading Symbol**: BDPT (OTC Pink Sheets).
- **Headquarters**: 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128.
- **Employees**: 3 full-time executive employees and 3 part-time employees in 2023.

## Core Business
BioAdaptives, Inc. operates in the health and wellness industry, focusing on the investigation, marketing, and distribution of natural plant, algal, and mushroom-based products and medical devices aimed at improving health and wellness for both humans and animals. The primary product emphasis includes:

- **Human Products**: Targeted towards pain relief, anti-viral functions, and anti-aging properties.
- **Animal Products**: Specifically formulated products for equine and canine health.

### Current Product Offerings
#### Human Products
1. **PluriPain®**: All-natural pain relief formulation.
2. **MindNMemory™**: Nootropic formulation enhancing memory, focus, and mental clarity.
3. **SleepEZ™**: A natural soporific for relaxing and improving sleep quality.
4. **Cell Rejuven™**: Increases energy, mobility, and promotes hair and nail growth.
5. **ProteinNMore™**: Aids in building lean muscle and improving blood flow.
6. **Lung Flute™**: An FDA-cleared medical device for respiratory health.
7. **Upcoming Products**:
   - **PluriPain PMS™**: Designed for menstrual pain relief.
   - **VeganHepplus™**: Liver support supplement.
   - **NaturaComplete™**: An all-in-one dietary supplement targeting general health.

#### Animal Products
1. **Equine All-in-One™**: Formulation offered to trainers and horse owners.
2. **Equine All-in-One Plus™**: Enhanced version for better results.
3. **Canine All-in-One™**: Targeted to improve health in dogs.

### Customer Base
- **Human Products**: Direct web sales have not yet produced significant revenue.
- **Animal Products**: Exclusive distribution agreements, with FCBR Therapy Division reporting a 400% increase in wholesale volume in early 2023.

## Financials
- The company has reported that it requires additional financing to become commercially viable.
- As of December 31, 2023, revenues did not cover operating expenses, resulting in a reliance on external funding to support operations.

## Research and Marketing
- The company is actively pursuing scientific surveys to demonstrate the effectiveness of its products, though it does not anticipate developing FDA-approved testing protocols.
- Marketing strategies have included social media outreach, Amazon sales, and traditional advertising, with a focus on growing its presence among seniors and wellness-focused consumers.

## Future Outlook
With plans to launch NaturaComplete™ and further engage in AI-supported health solutions through partnerships, BioAdaptives aims to cater to a growing global demographic interested in wellness products, particularly among the aging population. Expansion efforts are also focused on international markets, including Asia, Australasia, the Middle East, and Europe.

## Risks and Challenges
- The company faces challenges related to competition in the nutraceutical industry, funding and cash flow fluctuations, reliance on key personnel, and regulatory compliance.
- BioAdaptives has not yet achieved a stable revenue stream and continues to rely on financing methods that may affect future equity.

---

### Key Statistics
- **Current Number of Employees**: 6 (3 full-time and 3 part-time).
- **Revenue**: Not specified, but operating expenses exceed revenue as of December 31, 2023.
- **Market Position**: Operating as a public company on the OTC market with limited trading activity. 

BioAdaptives is positioned in a competitive market, emphasizing its commitment to innovation and product development while navigating the challenges of building a sustainable business model.

BIOADAPTIVES, INC.

10-K / April 15, 2025

10-K / April 10, 2024

10-K / April 15, 2025

Company Summary: BioAdaptives, Inc.

Business Overview

Product Development

Market & Marketing

Manufacturing & Supplies

Financial & Operational Data

Additional Details